Tissue neutropenia: the newborn neutrophil in perspective.
The notion of tissue neutropenia due to impaired signal transduction secondary to decreased newborn neutrophil membrane receptor mobility allows intervention to improve neutrophil mobilization. New pharmacologic agents and biologic response modifiers show promise of increasing the newborn neutrophil's ability to respond to chemotactic signals. This approach will lead to the development of effective adjuvant therapy for neonatal sepsis.